Briggs Morrison - 12 Jun 2025 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)

Reporting relationship: Director
Issuer ticker: HOWL
Reported as of: 12 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2025, 16:10:15 UTC
Prior SEC filing: 06 Jun 2025
Next SEC filing: 27 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Owen, Attorney-in-fact

Key filing fact

Briggs Morrison filed Form 4 for Werewolf Therapeutics, Inc. (HOWL) on 13 Jun 2025.

Key facts

This page summarizes Briggs Morrison's Form 4 filing for Werewolf Therapeutics, Inc. (HOWL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2025, 16:10.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001654430 Primary reporting owner

Morrison Briggs

Relationship: Director
Address: C/O WEREWOLF THERAPEUTICS, INC., 200 TALCOTT AVENUE, 2ND FLOOR, WATERTOWN
Signature: /s/ Jonathan Owen, Attorney-in-fact
Signature date: 13 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HOWL transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +27,000
Change %
Price: $0.000000
Shares after: 27,000
Date: 12 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,000
Exercise price: $1.29
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.